The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma

Por Beard, S M, Lorigan, P C, Sampson, F C
Publicado em 2000

TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes

Por Katerinaki, E, Evans, G S, Lorigan, P C, MacNeil, S
Publicado em 2003

Asthma in pregnancy complicated by iatrogenic pulmonary oedema.

Por Hardy, C. C., Lorigan, P., Ratcliffe, A., Carroll, K. B.
Publicado em 1989

Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis

Por Sharma, S, Jagdev, S, Coleman, R E, Hancock, B W, Lorigan, P C
Publicado em 1999

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactin...

Por Dobson, L S, Lorigan, P C, Coleman, R E, Hancock, B W
Publicado em 2000

Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.

Por Ferguson, J. E., Hulse, P., Lorigan, P., Jayson, G., Scarffe, J. H.
Publicado em 1995

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

Por Middleton, M R, Lorigan, P, Owen, J, Ashcroft, L, Lee, S M, Harper, P, Thatcher, N
Publicado em 2000

Investigation of female survival benefit in metastatic melanoma

Por Richardson, B, Price, A, Wagner, M, Williams, V, Lorigan, P, Browne, S, Miller, J G, Neil, S Mac
Publicado em 1999

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

Por Zekri, J M, Hough, R E, Davies, J M, Molife, R, Hancock, B W, Lorigan, P C
Publicado em 2003

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

Por Biswas, S, Wrigley, J, East, C, Hern, A, Marshall, A, Dunn, J, Lorigan, P, Middleton, M, Corrie, P
Publicado em 2008

Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

Por Gillespie, A. M., Lorigan, P. C., Radstone, C. R., Waterhouse, J. C., Coleman, R. E., Hancock, B. W.
Publicado em 1997

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

Por White, S C, Lorigan, P, Margison, G P, Margison, J M, Martin, F, Thatcher, N, Anderson, H, Ranson, M
Publicado em 2006

Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma

Por Hough, R E, Goepel, J R, Alcock, H E, Hancock, B W, Lorigan, P C, Hammond, D W
Publicado em 2001

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

Por Baka, S, Califano, R, Ferraldeschi, R, Aschroft, L, Thatcher, N, Taylor, P, Faivre-Finn, C, Blackhall, F, Lorigan, P
Publicado em 2008

High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia

Por El-Helw, L M, Seckl, M J, Haynes, R, Evans, L S, Lorigan, P C, Long, J, Kanfer, E J, Newlands, E S, Hancock, B W
Publicado em 2005

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

Por Plummer, R, Lorigan, P, Brown, E, Zaucha, R, Moiseyenko, V, Demidov, L, Soriano, V, Chmielowska, E, Andrés, R, Kudryavtseva, G, Kahatt, C, Szyldergemajn, S, Extremera, S, de Miguel, B, Cullell-Young, M, Calvert, H
Publicado em 2013

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

Por Khan, O A, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A J, McGown, G, Thorncroft, M, Margison, G P, Califano, R, Larkin, J, Wellman, S, Middleton, M R
Publicado em 2011

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA

Por Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., Marais, R.
Publicado no Ann Oncol (2016)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Por Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E
Publicado em 2011

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Por Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Publicado no Br J Cancer (2016)